The impact of primary radical treatment on the effectiveness and safety of systemic treatment with ribociclib in female patients with advanced breast cancer

Abstract

Aim of the study: To assess the impact of primary radical treatment on the effectiveness and safety of systemic treatment with ribociclib in patients with advanced breast cancer.

Material and methods: Retrospective data analysis of 180 patients with advanced breast cancer undergoing systemic treatment with ribociclib. The study included a retrospective analysis of data from 180 patients with advanced breast cancer undergoing systemic treatment with ribociclib. The study group included 106 (59%) patients who underwent radical treatment at earlier stages. The control group consisted of 74 patients (41%) diagnosed at an advanced stage.

Results: The analysis showed that progression-free survival is longer in patients with primary advanced disease compared to patients with a history of radical treatment. The median PFS is 21.91 months for patients with a history of radical treatment, while for primary patients it is longer than the total observation time (p = 0.049). The median overall survival time did not reach statistical significance and was longer than the time of observation for both groups. In this study, it was observed that the most common adverse event was haematological complications. Neutropenia of any grade was observed in 82.78% of all patients, including G3/G4 neutropenia in 43.89% of patients. Anaemia of any degree was observed in 62.78% of patients, including G3/G4 anaemia in 1.67% of patients. Thrombocytopenia of any degree was observed in 62.78%. For the above complications, no statistically significant differences were observed between the study group and the control group.

Conclusions: A higher benefit (expressed in PFS) from the use of ribociclib will be achieved by patients whose treatment was initiated at a locally advanced or metastatic stage compared to patients with a history of radical treatment of breast cancer. A history of primary radical treatment has no impact on either overall survival or the safety profile of ribociclib treatment.